- Home
- FFC vs GHRS Comparison
FFC vs GHRS Comparison
Compare FFC & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFC
- GHRS
- Stock Information
- Founded
- FFC 1983
- GHRS 2018
- Country
- FFC United States
- GHRS Ireland
- Employees
- FFC N/A
- GHRS N/A
- Industry
- FFC Trusts Except Educational Religious and Charitable
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- FFC Finance
- GHRS Health Care
- Exchange
- FFC Nasdaq
- GHRS Nasdaq
- Market Cap
- FFC 798.8M
- GHRS 774.1M
- IPO Year
- FFC N/A
- GHRS 2021
- Fundamental
- Price
- FFC $16.75
- GHRS $13.50
- Analyst Decision
- FFC
- GHRS Strong Buy
- Analyst Count
- FFC 0
- GHRS 9
- Target Price
- FFC N/A
- GHRS $29.33
- AVG Volume (30 Days)
- FFC 164.1K
- GHRS 278.7K
- Earning Date
- FFC 01-01-0001
- GHRS 11-07-2025
- Dividend Yield
- FFC 6.79%
- GHRS N/A
- EPS Growth
- FFC N/A
- GHRS N/A
- EPS
- FFC N/A
- GHRS N/A
- Revenue
- FFC N/A
- GHRS N/A
- Revenue This Year
- FFC N/A
- GHRS N/A
- Revenue Next Year
- FFC N/A
- GHRS N/A
- P/E Ratio
- FFC N/A
- GHRS N/A
- Revenue Growth
- FFC N/A
- GHRS N/A
- 52 Week Low
- FFC $11.90
- GHRS $6.72
- 52 Week High
- FFC $14.96
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- FFC 52.49
- GHRS 49.82
- Support Level
- FFC $16.52
- GHRS $12.50
- Resistance Level
- FFC $16.89
- GHRS $14.77
- Average True Range (ATR)
- FFC 0.14
- GHRS 0.99
- MACD
- FFC 0.01
- GHRS -0.00
- Stochastic Oscillator
- FFC 62.16
- GHRS 44.04
About FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.